Literature DB >> 15007269

Impact of morphology and biology on the prognosis of patients with gliomas.

Inga Gudinaviciene1, Darius Pranys, Elona Juozaityte.   

Abstract

Gliomas are the most common type of primary intracerebral neoplasm. They carry a dismal prognosis. The main prognostic factors are patient age, performance status and malignancy grade. Because patients with the same histologic diagnosis have variable outcomes, there is a need to develop better prognostic markers with the aim of predicting tumor behaviour and response to therapies. This paper reviews different morphological, genetic, molecular factors and their association with survival. Tumor associated morphological features such as predominant cell type, cellularity, cytological atypia, proliferation activity, microvascular proliferation, necrosis and apoptosis are discussed in some detail.

Entities:  

Mesh:

Year:  2004        PMID: 15007269

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  8 in total

1.  In vivo characterization of several rodent glioma models by 1H MRS.

Authors:  Sabrina Doblas; Ting He; Debra Saunders; Jessica Hoyle; Nataliya Smith; Quentin Pye; Megan Lerner; Randy L Jensen; Rheal A Towner
Journal:  NMR Biomed       Date:  2011-09-23       Impact factor: 4.044

2.  Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography.

Authors:  Sabrina Doblas; Ting He; Debbie Saunders; Jamie Pearson; Jessica Hoyle; Nataliya Smith; Megan Lerner; Rheal A Towner
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

Review 3.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

4.  ELTD1, a potential new biomarker for gliomas.

Authors:  Rheal A Towner; Randy L Jensen; Howard Colman; Brian Vaillant; Nataliya Smith; Rebba Casteel; Debra Saunders; David L Gillespie; Robert Silasi-Mansat; Florea Lupu; Cory B Giles; Jonathan D Wren
Journal:  Neurosurgery       Date:  2013-01       Impact factor: 4.654

5.  ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas.

Authors:  Regislaine Valéria Burim; Silvia Aparecida Teixeira; Benedicto Oscar Colli; Fernanda Maris Peria; Luis Fernando Tirapelli; Suely Kazue Nagahashi Marie; Suzana Maria Fleury Malheiros; Sueli Mieko Oba-Shinjo; Alberto Alain Gabbai; Paulo Andrade Lotufo; Carlos Gilberto Carlotti-Júnior
Journal:  Clin Exp Med       Date:  2009-03-21       Impact factor: 3.984

6.  Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.

Authors:  Yolanda Ruano; Manuela Mollejo; Teresa Ribalta; Concepción Fiaño; Francisca I Camacho; Elena Gómez; Angel Rodríguez de Lope; Jose-Luis Hernández-Moneo; Pedro Martínez; Bárbara Meléndez
Journal:  Mol Cancer       Date:  2006-09-26       Impact factor: 27.401

7.  Postoperative functional status in patients with supratentorial superficial low-grade glioma.

Authors:  Ji Zhang; Yin Sheng Chen; You-Ping Li; Zheng-Quan Zhu; Jian-Min Liu; Cheng-Cheng Guo; Qun-Ying Yang; Xiao-Li Wang; Ying-Hua Rao; Qing Mao; Wen-Yan Li; Lu Ma; Yun Qiang Yang; Shi-Yin Xiao
Journal:  World J Surg Oncol       Date:  2017-10-17       Impact factor: 2.754

8.  Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome.

Authors:  Shiran Ferber; Galia Tiram; Ana Sousa-Herves; Anat Eldar-Boock; Adva Krivitsky; Anna Scomparin; Eilam Yeini; Paula Ofek; Dikla Ben-Shushan; Laura Isabel Vossen; Kai Licha; Rachel Grossman; Zvi Ram; Jack Henkin; Eytan Ruppin; Noam Auslander; Rainer Haag; Marcelo Calderón; Ronit Satchi-Fainaro
Journal:  Elife       Date:  2017-10-04       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.